

IFV



ABX-PF1 DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski
Group : 1644
Applicants : Douglas Charles Hanson et al.
Application No. : 10/612,497
Confirmation No. : 3552
Filed : July 1, 2003
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York
April 1, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL LETTER SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Transmitted herewith is a Supplemental Information Disclosure Statement and copies of the documents cited therein in the above-identified application.

This Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311. In accordance with 37 C.F.R. § 1.97 (c), this Statement is accompanied by a check for \$180.00, which is the fee as set forth in 37 C.F.R. § 1.17(p).

The Director is hereby authorized to charge payment of any additional fees required in connection with the accompanying Supplemental Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)

Attorney for Applicants

c/o FISH & NEAVE IP GROUP

ROPES & GRAY LLP

Customer No. 1473


1251 Avenue of the Americas

New York, New York 10020-1105

Tel.: (212) 596-9000

Fax.: (212) 596-9090

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

4-1-05

Irene Kaelman
Signing



ABX-PF1 DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski
Group : 1644
Applicants : Douglas Charles Hanson et al.
Application No. : 10/612,497
Confirmation No. : 3552
Filed : July 1, 2003
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York
April 1, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make of record the documents listed below. Copies of all non-United States Patent documents are enclosed.¹

04/07/2005 HDEHESS1 00000045 10612497

01 FC:1806

180.00 0P

¹ For the Examiner's convenience, applicants have also enclosed a completed Form PTO/SB/08A, listing these documents.

FOREIGN PATENT DOCUMENTS

European Patent 0 239 400, (Winter) published August 3, 1994.

OTHER DOCUMENTS

Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature*, 321:522-525 (1986).

Morrison, "Transfectomas provide novel chimeric antibodies," *Science*, 229:1202-1207 (1985).

Oi et al., "Chimeric antibodies," *Biotechniques*, 4(3):214-221 (1986).

Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function," *Nature*, 314:268-270 (1985).

O'Kennedy et al., "Antibody engineering: an overview," *Essays in Biochemistry*, 46:59-75 (1991).

Parren, "Preparation of genetically engineered monoclonal antibodies for human immunotherapy," *Human Antibodies and Hybridomas*, 3:137-145 (1992).

Riechmann et al., "Reshaping human antibodies for therapy," *Nature*, 332:323-327 (1988).

Vaswani et al., "Humanized antibodies as potential therapeutic drugs," *Annals of Allergy, Asthma & Immunology*, 81:105-119 (1998).

Verhoeyen et al., "Reshaping human antibodies: grafting an antilysozyme activity," *Science*, 239:1534-1536 (1988).

Wu, "From esoteric theory to therapeutic antibodies," *Applied Biochemistry and Biotechnology*, 47(2/3):107-118 (1994).


REMARKS

Applicants request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application and (2) printed on any patent issuing from this application. Applicants also request that the Examiner initial the enclosed Form PTO/SB/08A in the appropriate places to indicate that the documents have been considered and return a copy of the initialed Form to the undersigned in accordance with MPEP § 609 and § 2001.06(b).

This Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

In accordance with 37 C.F.R. § 1.97 (c), this Statement is accompanied by a check for \$180.00, which is the fee as set forth in 37 C.F.R. § 1.17(p). The Director is hereby authorized to charge payment of any additional fees required in connection with the accompanying Supplemental Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 06-1075.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)

Attorney for Applicants

c/o FISH & NEAVE IP GROUP

ROPES & GRAY LLP

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1105

Tel.: (212) 596-9000

Fax.: (212) 596-9090